Human health risk assessment (HHRA) must be adapted to the challenges of the 21st century, and the use of toxicogenomics data in HHRA is among the changes that regulatory agencies worldwide are trying to implement. However, the use of toxicogenomics data in HHRA is still limited. The purpose of this study was to explore the availability, quality, and relevance to HHRA of toxicogenomics publications as potential barriers to their use in HHRA. We conducted a scoping review of available toxicogenomics literature, using trihalomethanes as a case study. Four bibliographic databases (including the Comparative Toxicogenomics Database) were assessed. An evaluation table was developed to characterize quality and relevance of studies included on the basis of criteria proposed in the literature. Studies were selected and analyzed by 2 independent reviewers. Only 9 studies, published between 1997 and 2015, were included in the analysis. Based on the selected criteria, critical methodological details were often missing; in fact, only 3 out of 9 studies were considered to be of adequate quality for HHRA. No studies met >3 (out of 7) criteria of relevance to HHRA (eg, adequate number of doses and sample size). This first scoping review of toxicogenomics publications on trihalomethanes shows that low availability, quality, and relevance to HHRA of toxicogenomics publications presents potential barriers to their use in HHRA. Improved reporting of methodological details and study design is needed in the future so that toxicogenomics studies can be appropriately assessed regarding their quality and value for HHRA.
pathways of toxicity (Ancizar-Aristiz abal et al., 2015; EFSA, 2014; NASEM, 2017; NRC, 2007a) . These methods should impact various issues of human health risk assessment (HHRA) .
Recent publications have demonstrated the usefulness of toxicogenomics data, either as stand-alone results to predict toxicity and generate reference values (see case studies on acetaminophen, Kienhuis et al., 2011; and benzo[a] pyrene, Chepelev et al., 2015; Moffat et al., 2015) or as supportive of the traditional risk assessment process to better understand mechanisms of action of chemicals through their integration in adverse outcome pathways linking molecular changes with known phenotypes (see the case study on dibutyl phthalate, Euling et al., 2013a ; and work by Koedrith et al., 2015; Sturla et al., 2014; Wilson et al., 2013) .
Toxicogenomics has the potential to address some weaknesses and uncertainties inherent to traditional HHRA: intraand interspecies extrapolation, low-dose responses, genetic variability, exposure assessment, and dose-response modeling to establish intermediate molecular steps (CCA, 2012; McHale et al., 2010; Moffat et al., 2015; Mortensen and Euling, 2013; NASEM, 2017; NRC, 2007a,b; Sturla et al., 2014) .
In the last decade, regulatory agencies in North America and Europe have recommended the integration of toxicogenomics data in their HHRA process (CCA, 2012; EFSA, 2014; NASEM, 2017; NRC, 2007a,b; Tralau et al., 2015; U.S. EPA, 2014) . However, a recent publication emphasized that, despite this desire to modernize the way HHRA is conducted, the use of toxicogenomics data and information in HHRA appears to be still limited . Many factors could account for this situation, including the limited availability of toxicogenomics data. In fact, multiple authors identified low availability, low quality, or low methodological relevance of toxicogenomics studies and data as main limitations to their integration in HHRA. These limitations are exacerbated by the limited availability of guidelines regarding the design of toxicogenomics studies and the reporting of results-except in the pharmaceutical field (Birnbaum et al., 2016; Euling et al., 2013a; Goetz et al., 2011; Marx-Stoelting et al., 2015; Moffat et al., 2015; Vachon et al., 2017; Zaunbrecher et al., 2017) . Efforts are being made to develop better guidelines, and criteria related to toxicogenomics data quality and relevance to HHRA have been proposed in the literature Chepelev et al., 2015; Goetz et al., 2011; McConnell et al., 2014; McHale et al., 2010; RathahaoParis et al., 2016) . Such criteria can serve either to assess the quality of toxicogenomics studies and their relevance to HHRA, or as guidance for epidemiologists and laboratory toxicologists in the process of designing their own studies.
Disinfection by-products (DBPs) are a class of molecules formed during the drinking water disinfection process. More than 600 DBPs have been detected in drinking and pool water to this day. Many of them are known to be toxic (Richardson et al., 2007) . Trihalomethanes (THMs), a class of DBPs among which 4 compounds are regulated (chloroform, bromodichloromethane [BDCM] , dibromochloromethane [DBCM] , bromoform) are among the most studied (Plewa and Wagner, 2015) . They are associated with adverse health effects, such as increased risk of cancer (bladder, colorectal) and adverse pregnancy outcomes (Grazuleviciene et al., 2013; Grellier et al., 2010; Hrudey and Fawell, 2015; Levallois et al., 2012; Villanueva et al., 2015) . However, uncertainties persist regarding their mechanisms of action and challenges remain in the assessment of the risk posed by THMs at low doses (Borgert et al., 2015; Grellier et al., 2015; Hrudey and Fawell, 2015; Plewa and Wagner, 2015; Stalter et al., 2016) .
In this paper, a scoping review was preferred over a systematic review because of its exploratory approach, which better fits with this new subject of research (Arksey and O'Malley, 2005) . Indeed, scoping reviews aim to systematically "map the literature on a particular topic or research area and provide an opportunity to identify key concepts; gaps in the research; and types and sources of evidence to inform practice, policymaking, and research" (Daudt et al., 2013) . The present scoping review aims to: (1) characterize available toxicogenomics studies on THMs to assess their availability, quality, and usefulness to HHRA using criteria extracted from the literature, and (2) to experiment using methodological quality criteria for the potential inclusion of toxicogenomics studies in HHRA and report on our experience. THMs were used only as a case study, and it was not the objective of this study to draw conclusions about their toxicity.
MATERIALS AND METHODS

Literature Review Strategy
Four electronic databases were searched (last date: January 13, 2016): MEDLINE complete (through EBSCOhost), Embase (1974-to date, through OvidSP), Web of Science (1900-to date), and the Comparative Toxicogenomics Database (CTD), specializing in gene expression data related to environmental (chemical) exposure (Davis et al., 2009 (Davis et al., , 2015 . No date, language, or publication type limits were applied to the electronic search. Keywords comprised terms associated with toxicogenomics methods and data, such as epigenetics, transcriptomics, proteomics, metabolomics, microarray, gene expression, quantitative polymerase chain reaction (qPCR), upregulation, and downregulation), including the names of the 4 THMs compounds (chloroform, BDCM, DBCM, bromoform, and synonymous names, such as trichloromethane). The search involved both natural and controlled vocabulary (MeSH, EMTREE), when applicable. Complete search strategy details, elaborated with the help of a librarian specialized in literature review, are available in Supplementary Table 1. All citations were imported to Zotero reference management software (www.zotero.org, Roy Rosenzweig Center for History and New Media, Fairfax, Virginia). Duplicates were hand-removed.
Study Selection and Eligibility
Studies were eligible and included in the analysis if: (1) they were original toxicological (in vivo or in vitro) or epidemiological research studies, (2) the toxicity of one or several regulated THMs (chloroform, BDCM, DBCM, or bromoform) was investigated, and (3) global toxicogenomics analysis (ie, of the whole epigenome, transcriptome, proteome, or metabolome) was performed. Studies performing global toxicogenomics analysis were targeted because of their broader potential to inform all stages of the HHRA process, beyond the characterization of the mechanisms of action.
Studies were excluded if: (1) they were literature reviews or methods and models validation, (2) the regulated THM compound (eg, chloroform) was used only as a control, or (3) only targeted analysis (eg, of a subset of genes or metabolites) were performed.
All publications were screened by 2 independent investigators (J.V. and F.P.L.) who compared and discussed any uncertainties in study selection to prevent screening errors or misinterpretation of studies' methods. A third investigator (C.C.) was available to resolve disagreement between the 2 main investigators. Investigators were not blinded to author and journal names. Citations were screened based on their title, abstract, and full text. All articles included from the full text screening were compared and discussed until a final set of eligible studies was agreed on. This final set of studies was included for evaluation and analysis as described in the section below.
Study Evaluation and Analysis
Only the final set of included studies were analyzed. In order to address the first objective, data from all included articles were compiled in a spreadsheet version of Table 1 ( MS Excel, Microsoft Corporation, 2013) for comparison and analysis (available in Supplementary Table 2). Table 1 was composed of 3 distinct sections (presented below) relating to the 3 main analysis axes of the objective: availability of data, methodological quality, and methodological relevance to HHRA. The table was elaborated using multiple criteria proposed in specialized literature Chepelev et al., 2015; Goetz et al., 2011; McHale et al., 2010; Rathahao-Paris et al., 2016) and was reviewed by 2 toxicogenomics experts prior to the conduct of the study. Briefly, each included study was assigned a row, and extracted data (either text snippet extracted from the article, or yes/no) was inserted in the columns' cells corresponding to the appropriate criteria.
Section 1: General methodological characteristics of included studies. The first section was dedicated to the description of general methodological characteristics of each included studies, such as study type, molecule(s) studied, human and/or animal sample(s), and treatments (Table 1 , section 1). This information was used to characterize the availability of toxicogenomics studies on THMs by study type, by molecule(s) investigated, and by genomics methods used. Analysis consisted of calculating frequencies for the methodological characteristics (eg, number of studies performing microarrays). Some of the methodological characteristics included in this section (eg, sample size, exposure and treatment scenario, substance vehicle, presence of control) were for information purposes only and to facilitate the evaluation of the methodological relevance to HHRA in section 3.
Section 2: Methodological quality evaluation of included studies. This second section of the table focused on the evaluation of each included studies' quality for potential use in the HHRA process, specifically for the hazard identification and dose-response assessment phases (Table 1, section 2). This evaluation was solely based on methodological quality criteria proposed by BourdonLacombe et al. (2015) to which studies must satisfy in order to be considered in HHRA, and that were developed to guide risk assessors considered nonspecialized in toxicogenomics. However, in the present study, these criteria were not used to exclude studies already included for analysis, but rather to calculate how many of these would be considered or rejected in a HHRA process. Other quality criteria were optional and informative only (in italic in Table 1 , section 2; eg, statistical significance criteria used in studies). Although sharing similar criteria for RNA-based analysis work, McConnell et al. (2014) criteria were not used because they were restricted to transcriptomics analyses and their targeted audience were risk assessors specialized in toxicogenomics.
Quality was assessed individually for each included study. To be deemed of acceptable quality for potential use in HHRA, a study must satisfy all applicable methodological quality criteria (Table 1 , section 2). Studies were subdivided according to molecules investigated and methods performed, and the proportion of studies satisfying all applicable methodological quality criteria was calculated for each.
Section 3: Evaluation of methodological relevance to HHRA of included studies. The third section of Table 1 regrouped criteria related to included studies' relevance (or usefulness) to HHRA that were discussed in the literature Goetz et al., 2011; McHale et al., 2010) . Some of these criteria shared similarities with methodological quality criteria. However they were not used to evaluate the potential inclusion or exclusion of studies in HHRA. In fact, relevance to HHRA criteria indicated a preferred or alternative study design that broadens studies' potential use in HHRA (ie, beyond just the characterization of the mechanisms of action). As an example, a study satisfying none of the relevance to HHRA criteria could still be deemed informative for some aspects of HHRA if of adequate quality, and a study could be expected to satisfy only a few of these criteria depending on its objective (eg, hazard identification, doseresponse characterization). Analysis of studies' relevance to HHRA consisted of calculating the proportions of studies satisfying each relevance to HHRA criteria.
RESULTS
Search Strategy and Selection of Toxicogenomics Studies
Detailed steps of studies' identification and inclusion can be visualized in the Prisma flowchart presented in Figure 1 . The research strategy completed on January 13, 2016, generated 2560 citations, 722 of which were excluded as they were duplicates, leaving 1838 citations for screening titles and abstracts. Only 18 citations either met the eligibility criteria or could not be assessed properly from the title and abstract. Full texts of these 18 citations were reviewed, resulting in the exclusion of 9 studies that did not meet the eligibility criteria after careful evaluation of their methodologies: 5 of them only performed targeted analyses, 2 were not original toxicological or epidemiological studies, and 2 did not investigate 1 or many THMs on their own. Nine studies were left for data extraction and comprehensive analysis. All eligible studies were in English. There was no significant disagreement during the selection process.
General and Methodological Characteristics of Included Studies
Study Type and Molecules Investigated Of the 9 studies included for analysis, 8 were toxicological (Coffin et al., 2000; Gvakharia et al., 2007; Hosohata et al., 2011; Kegelmeyer et al., 1997; Kier et al., 2004; Ozden et al., 2015; Pereira et al., 2004; Tao et al., 2005) , and only 1 was epidemiological . Date of publication ranged from 1997 to 2015. Of the toxicological studies, 6 assessed chloroform (Coffin et al., 2000; Gvakharia et al., 2007; Hosohata et al., 2011; Kegelmeyer et al., 1997; Kier et al., 2004; Ozden et al., 2015) and 3 assessed BDCM (Coffin et al., 2000; Pereira et al., 2004; Tao et al., 2005) . No studies examined DBCM or bromoform. The epidemiological study examined all 4 THMs as lifetime averages of their sum. Details of all 9 studies appear in Supplementary Table 2.
Epidemiological and Toxicological Models
The epidemiological study analyzed whole blood samples . In vivo models were the most common study design (n ¼ 7), with F344 rats (n ¼ 3) and B6C3F1 mice (n ¼ 4) being the 
Yes/No
The data take into consideration potential confounding effects Yes/No In vivo animal Control animals were handled alongside treated animals using identical procedures (eg, controls in oral gavage experiments received vehicle only) and at similar times
If temporality is considered, time-matched controls were used Yes/No A minimum of 3 biological replicates (animals) were used per group (in order to reach desired power)
In vitro Cytotoxicity was assessed, and at least some of the concentrations are below those inducing overt toxicity Yes/No most prevalent. One study involved Sprague Dawley rats (Kier et al., 2004) . In vitro models were less studied (n ¼ 3): Only primary human renal cells (Hosohata et al., 2011) , human hepatocytes (Kier et al., 2004) , and ammonia-oxidizing bacteria (Nitrosomonas europaea) (Gvakharia et al., 2007) were used. One study reported both in vivo and in vitro investigations (Kier et al., 2004) .
Genomics Analysis
Transcriptomics analysis using RNA microarray was the most frequent genomics method employed (n ¼ 3), followed by DNA methylation microarray (n ¼ 2), global DNA methylation by dot-blot analysis (n ¼ 2), mRNA levels assessment by differential display technique (n ¼ 1), global DNA methylation analysis by high performance liquid chromatography (HPLC) (n ¼ 1) or liquid chromatography-tandem mass spectrometry (LC-MS/MS) (n ¼ 1). RNA sequencing was not undertaken in any of the studies, and none of them investigated the proteome or the metabolome.
Methodological Quality of Included Studies for Potential Use in HHRA
By Chemicals
Chloroform. Of the 6 toxicological studies examining the toxicogenomics impact of chloroform, only 1 of them (Coffin et al., 2000) met all applicable methodological quality criteria in Table 1 . However, the method employed in this study (ie, HPLC) was not addressed in Bourdon-Lacombe et al. (2015), and no criteria regarding this method were present in the evaluation table. Thus, the only applicable methodological quality criteria which were met were those associated with in vivo methodology.
Bromodichloromethane. The 3 studies examining BDCM by in vivo methods satisfied all applicable methodological quality criteria (Coffin et al., 2000; Pereira et al., 2004; Tao et al., 2005) . However, the only applicable quality criteria were those specific to in vivo methodology, because the analytical techniques deployed were "older" (eg, dot-blot analysis) and were not addressed in Bourdon-Lacombe et al. (2015) . In fact, these publications on BDCM dated back to 2005, 2004 , and 2000, and although they are still valid it is unlikely that such methods would be still considered today in global toxicogenomics analysis.
Total trihalomethanes. The epidemiological study that examined all 4 THMs (as averages of life-time exposure) met only some methodological quality criteria related to in vivo human methodology . Confounding factors were only partially considered as only generic factors such as age, sex, municipality, highest education, and smoking were considered; authors did not address lifestyle individual factors such as diet and exercise that could affect DNA methylation (McHale et al., 2010) . Moreover, exposure to other chemicals could not be considered negligible as total THMs were used as proxy of exposure to other DBPs, which is subject to debate as variations in THMs do not always reflect variations in other DBPs or other substances (Plewa and Wagner, 2015) .
By Study Methods
Microarray. All 5 studies involving microarrays satisfied both quality criteria specific to this method (1) "The data were preprocessed (eg, background subtracted and log transformed) and normalized (ie, adjusted to remove technical variations between arrays) prior to statistical analysis"; (2) "An appropriate statistical analysis of data was conducted to identify differentially expressed genes") (Gvakharia et al., 2007; Hosohata et al., 2011; Kier et al., 2004; Ozden et al., 2015; Salas et al., 2015) .
RNA sequencing. No studies used this method.
By Study Models
In vitro. None of the 3 studies that conducted in vitro investigations met all 3 methodological quality criteria related to in vitro techniques. Because of lack of information, the criterion "Unexposed control cells were cultured at the same time as the treated cells using identical cell culture procedures" could not be properly assessed in Hosohata et al. (2011) , while "A minimum of 3 experimental replicates (plates) were used (in order to reach desired power)" could not be properly assessed in Kier et al. (2004) . The study by Gvakharia et al. (2007) did not assess cytotoxicity.
In vivo. In vivo (animal) methodologies were generally well designed, with all but 1 criterion met across 6 applicable studies (Kegelmeyer et al., 1997, having sample size < 3), as was expected considering the prevalence of these methods in toxicology and the availability of guidelines from regulatory agencies. The epidemiological study, as mentioned earlier, did not satisfy 2 of the 4 applicable methodological quality criteria. Overall, 6 out of the 9 included studies did not meet all applicable methodological quality criteria, meaning they would not be considered for use in HHRA (Gvakharia et al., 2007; Hosohata et al., 2011; Kegelmeyer et al., 1997; Kier et al., 2004; Ozden et al., 2015; Salas et al., 2015) .
Although considered as an optional methodological quality criterion, it is noteworthy that most studies missed some information on statistical analysis (eg, p values, fold-change). This information is helpful for independent evaluation of study results and interpretation. Table 2 lists studies satisfying the relevance to HHRA criteria. Briefly, only 1 relevance to HHRA criterion (phenotypic anchoring, ie, anchoring genomics responses to physiological endpoints) was met by all 9 studies. Most of them did not use a minimum of 3 doses plus a control: Only 2 out of 9 studies satisfied this criterion (Kegelmeyer et al., 1997; Ozden et al., 2015) . About half of them had sample sizes 4 (in vivo n 4 animals per group; in vitro n 4 replicates per treatment) (4/9 studies, 1 unknown) (Coffin et al., 2000; Pereira et al., 2004; Salas et al., 2015; Tao et al., 2005) or various exposure durations (4/9 studies) (Kegelmeyer et al., 1997; Pereira et al., 2004; Salas et al., 2015; Tao et al., 2005) . Only 1 study (1/8, not applicable to the epidemiological study) collected samples at different times after the last exposure (Kier et al., 2004) . Use of human cells in vitro was limited, with only 2 studies (2/8, not applicable to the epidemiological study) testing either renal cells (Hosohata et al., 2011) or hepatocytes (Kier et al., 2004) . Finally, data from only 1 study was available publicly (1/9) (Gvakharia et al., 2007) . No study met >3 out of 7 criteria of relevance to HHRA.
Methodological Relevance of Included Studies to Human Health Risk Assessment
Main Results From Trihalomethanes Studies Satisfying the Methodological Quality Criteria
For interested readers, a short summary of the results from the 3 studies satisfying the methodological quality criteria is available in Supplementary File S4.
DISCUSSION
This paper provides for the first time an overview of the potential use and inclusion in HHRA of peer-reviewed toxicogenomics studies (toxicological and epidemiological) conducted on THMs by assessing their quality and relevance. We also reflect on limitations of the quality criteria used and propose some recommendations related to study design to increase the number of toxicogenomics publications considered in HHRA.
Principal Findings of the Scoping Review
The availability of toxicogenomics data on THMs is very limited in terms of numbers (only 9 studies identified according to the criteria used), and utility in HHRA. Governmental health risk assessments of THMs generally examine the 4 THMs chloroform, BDCM, DBCM, and bromoform, as they are usually regulated as their sum. The present review found no toxicogenomics studies investigating the health impacts of DBCM or bromoform, as most of them focused on chloroform, although evidence is growing that brominated THMs are more toxic even at low concentrations (Richardson et al., 2007) . Only 1 epidemiological study was identified in this scoping review. However, it is expected that more epidemiologists will start to use omics technologies for their investigations in the near future, as there is a growing interest regarding genomics study design and analysis in that field (Foxman and Martin, 2015; Nair et al., 2014; Tzoulaki et al., 2014) . Only one-third of the identified studies met all applicable methodological quality criteria. It suggests that study quality can impede the use of toxicogenomics data on THMs in HHRA. This does not necessarily imply the absence of scientific value, but indicates that the regulatory-related information needed to evaluate quality, based on methodological quality criteria, was either not included in these articles (in which case quality could not be verified) or not satisfied. In fact, many quality criteria aimed to establish the presence (and not the content) of methodological information, emphasizing the importance of adequate reporting of toxicogenomics method Goetz et al., 2011) and ensuring that toxicologists and epidemiologists are familiar with the way HHRA is conducted (Birnbaum et al., 2016) . This challenge is not limited to toxicogenomics publications, but rather represent an ongoing concern in HHRA (Å gerstrand et al., 2014; Molander et al., 2017). Moreover, the included toxicogenomics studies showed various degrees of relevance to HHRA, further emphasizing the need to inform toxicologists and epidemiologists about HHRA while keeping in mind that this could also be explained by financial or technical limitations. It is noteworthy that all studies were adequate regarding the concept of phenotypic anchoring, which is key to building regulatory confidence in toxicogenomics methods and identified pathways of toxicity (through reduced risks of mis-or overinterpretation of the observed molecular changes) that will ultimately serve as markers (Boverhof et al., 2011; Marx-Stoelting et al., 2015) .
Although these results show that the toxicogenomics publications on THMs are limited-regarding availability, quality, and relevance to HHRA-they indicate that other toxic chemicals could potentially suffer from a similar dearth of data.
Finally, only 5 out of the 9 included studies (Coffin et al., 2000; Hosohata et al., 2011; Kegelmeyer et al., 1997; Kier et al., 2004; Tao et al., 2005) were available in the CTD, suggesting that an exhaustive literature review of multidisciplinary databases (eg, Embase) is required to capture all relevant toxicogenomics publications that are not indexed in the databases integrated in the CTD. All included studies were available through Embase, 6 of them were available through Web of Science (Coffin et al., 2000; Gvakharia et al., 2007; Kegelmeyer et al., 1997; Ozden et al., 2015; Salas et al., 2015; Tao et al., 2005) , and only 4 out of the 9 were available through MEDLINE (Coffin et al., 2000; Gvakharia et al., 2007; Kegelmeyer et al., 1997; Salas et al., 2015) . For more information about systematic literature review for HHRA, the reader is referred to Rooney et al. (2014) .
Strengths and Limitations
Very few attempts to take a systematic approach to assess and characterize quality and the relevance of toxicogenomics studies for use in HHRA have been undertaken (McConnell et al., 2014) . Our attempt was based on criteria proposed in the literature and expert opinion Chepelev et al., 2015; Goetz et al., 2011; McHale et al., 2010; Rathahao-Paris et al., 2016) , with an emphasis on proposed guidelines for quality assessment by Bourdon-Lacombe et al. (2015) . This attempt allowed us to develop a simple tool that can be applied to methodologically various toxicogenomics studies and focuses on the inclusion of studies in the whole HHRA process, rather than solely focusing on characterization of mechanisms of action. This tool is made available for improvement and to further assess toxicogenomics publications on other molecules (in Excel format in Supplementary Table 3 ). The strength of the tool is that it covers different types of genomics methods, whereas other proposed tools or guidelines mostly focus on transcriptomics analysis using RNA microarray. The exercise also allowed the analysis of limitations of the quality criteria, which are discussed below.
The Systematic Omics Analysis Review (SOAR) tool (McConnell et al., 2014 ) is a similar tool that also aim at systematically assessing toxicogenomics studies for use in HHRA; however it differs in scope. The SOAR tool focuses on transcriptomics studies using RNA microarrays and requires risk assessors to be familiar with microarray data. Our tool targets preferably risk assessors that are knowledgeable, but nonspecialized, in toxicogenomics and is broader in scope (covering a wider range of genomics methods), allowing the use of a single tool to assess multiple studies or studies performing different methods simultaneously.
The present study focused on publications that performed global toxicogenomics analysis. However, it should not be forgotten that targeted analyses (eg, of a subset of genes previously identified in a global toxicogenomics analysis) are generally considered in HHRA because they may provide significant mechanistic insights.
A first limitation of the methodological quality criteria used is that although they were designed for health risk assessors who are nonspecialized in toxicogenomics, some of them could be challenging to use and necessitate some training. A criterion for microarrays is "An appropriate statistical analysis of data was conducted to identify differentially expressed genes" (see Table 1 ), which requires some knowledge in specific statistical analysis of toxicogenomics data. Moreover, the statistical methods used to analyze toxicogenomics data vary in time and across studies, which exacerbates this difficulty. The same could be said for this criterion relating to epidemiological studies, "A sufficiently large sample size was used to ensure adequate power" (see Table 1 ), for which one could need to be knowledgeable about statistical particularities regarding power when dealing with toxicogenomics data. The other criteria used for the methodological quality assessment proved to be straightforward to use.
A second limitation is that although the quality criteria gather some information on methodological quality and relevance to HHRA, it does not capture whether a study's results are relevant to the questions that need answers regarding the chemical(s) assessed. Therefore, expert judgement is still needed past the initial screening phase (which could potentially be done by a risk assessor nonspecialized in toxicogenomics) when compiling and comparing results from studies to estimate human health hazards.
Finally, the tool's value is dependent on the available systematic quality criteria, therefore the limited number of published criteria for some of the genomics methods (eg, metabolomics, proteomics) makes it harder to assess studies using such analytical methods.
Recommendations for Further Work
Conduct further toxicogenomics studies to increase data availability. Generally, considering the benefits of toxicogenomics studies and the desire of regulatory agencies to increase their use of this type of data, laboratory toxicologists should consider genomics methods in addition to other traditional methods when designing their studies. For example, Integrated Approaches for Testing and Assessment (IATA) is an OECD initiative that aims to increase the understanding of both laboratory toxicologists and risk assessors on novel methodologies including toxicogenomics (IOMC, 2017) . IATA specifically focuses on encouraging toxicogenomics based risk assessment case studies and on developing guidance on how to produce and use toxicogenomics data. This, in turn, will strengthen our understanding of the links between traditional toxicological outcomes and pathway perturbations observed through genomics investigations, and contribute to address concerns regarding the use of this type of data in HHRA.
Improve reporting of critical studies' methodological details for appropriate quality assessment. Adequate reporting of methodological details is required to ensure that toxicogenomics studies can be appropriately assessed regarding their quality and value for HHRA, and thus increasing their chance of being included in HHRA. This consideration is not limited to toxicogenomics, but rather represents an ongoing challenge in the field of toxicology and HHRA (Å gerstrand et al., 2014; Samuel et al., 2016) . Although guidance is still limited, toxicologists and epidemiologists are encouraged to consult available publications on omics technologies for regulatory toxicology and toxicogenomics study design Chepelev et al., 2015; EFSA, 2014; Goetz et al., 2011; Horgan and Kenny, 2011; IOMC, 2017; McConnell et al., 2014; Nair et al., 2014; Tzoulaki et al., 2014) .
Consider the needs of HHRA in toxicogenomics study design. A few improvements to toxicogenomics study design would greatly increase their potential impact in HHRA, specifically for the hazard identification and dose-response assessment phases. For example, increasing the number of doses to a minimum of 3 (plus a control) would allow for mathematical modeling and more appropriate low-dose extrapolation. Sampling at various times after the last exposure would provide information on reversibility of the observed effects and inform on the mechanisms of action, considering that genomics mechanisms are dynamic and can change rapidly over time. Using human cells in in vitro investigations would reduce uncertainties associated with interspecies extrapolation, although it could bring other possible limitations Euling et al., 2013b; Goetz et al., 2011; McHale et al., 2010; Moffat et al., 2015; Tralau et al., 2015) .
Explore availability, quality, and relevance to HHRA in other case studies. Given the small number of toxicogenomics studies assessed in this study, other similar case studies should be conducted on other toxic chemical groups. This would allow comparison of barriers to the use of toxicogenomics in HHRA-ie, in terms of availability, quality, and relevance to HHRA-supporting the application of the 2 previous recommendations.
CONCLUSIONS
Using toxicogenomics studies on THMs, this scoping review characterized and assessed availability, quality of design and methodology, and relevance to HHRA as potential barriers to the use of toxicogenomics data in HHRA. Our review also shows that it is feasible to adopt a systematic approach to evaluate toxicogenomics study quality for HHRA, although the proposed criteria might have limited use considering the need for expert judgement in the HHRA steps subsequent to the screening of studies. We are confident that toxicogenomics study design and reporting of results will continue to improve in coming years, given that such research is funded and strategies are developed to better inform toxicologists and epidemiologists on the needs of HHRA. It is critical for studies to be designed and reported in ways that also optimize their usefulness in HHRA, thus increasing the quality of HHRA.
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